Welcome to our dedicated page for OnKure Therapeutics SEC filings (Ticker: OKUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for OnKure Therapeutics, Inc. (OKUR) provides access to the company’s official regulatory disclosures as a clinical-stage biopharmaceutical issuer listed on the Nasdaq Global Market. These documents offer detailed information about its precision oncology programs, financial condition, and capital markets activities, complementing the high-level descriptions found in press releases.
Through its periodic reports on Forms 10-K and 10-Q, OnKure describes its focus on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by current therapies. These filings expand on the company’s strategy around PI3Kα-targeted programs, including its lead candidate OKI-219 and its PI3Kα pan-mutant and other discovery-stage efforts, and include sections such as “Risk Factors” that outline scientific, clinical, regulatory, and financial risks.
Current reports on Form 8-K capture material events between periodic filings. For example, OnKure has filed 8-Ks to report quarterly financial results and to disclose entry into a sales agreement with Leerink Partners LLC for an at-the-market offering program of its Class A common stock. That agreement allows the company, subject to specified parameters and an effective shelf registration statement on Form S-3, to sell shares through Leerink Partners acting as sales agent, with compensation based on a percentage of gross proceeds.
On this page, users can review new and historical SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and registration statements such as Form S-3 referenced in the at-the-market program. Stock Titan’s tools apply AI-powered summaries to help explain the contents of lengthy filings, highlight key items like clinical development updates, capital raising arrangements, and risk disclosures, and make it easier to track how OnKure’s regulatory narrative evolves over time.
OnKure Therapeutics, Inc. entered into a private placement financing with institutional investors, agreeing to sell 26,713,636 Class A common shares at $4.15 per share and pre-funded warrants to purchase 9,430,959 shares at $4.1499 per underlying share, for expected gross proceeds of about $150.0 million before fees. The company plans to use the net proceeds to advance its next-generation PI3Kα pan-mutant programs in breast cancer and vascular anomalies and for working capital and general corporate purposes.
Investors receive registration rights for resale of the shares and warrant shares, and the lead investor obtains a board designee right, under which Dr. Liam Ratcliffe will join the board as a Class I director contingent on closing. Executives and directors agreed to a lock-up, and the company agreed to restrictions on new equity issuances and certain corporate actions for at least 180 days after closing and until the resale registration is effective. OnKure also provided pipeline updates, including plans to file INDs for OKI-345 and OKI-355 in the first half of 2027, progress in the PIKture-01 Phase 1a/1b trial of OKI-219, and a decision not to pursue further independent development of OKI-219 while it focuses on its PI3Kα pan-mutant inhibitors.
OnKure Therapeutics President and CEO Nicholas A. Saccomano reported a small tax-related sale of shares. He sold 86 shares of Class A Common Stock on March 23, 2026 at a weighted average price of $4.1565 per share.
According to the disclosure, these shares were automatically sold to cover tax withholding obligations tied to the vesting of restricted stock units under the company’s 2023 RSU Equity Incentive Plan. After this transaction, he directly holds 7,333 shares of Class A Common Stock.
OnKure Therapeutics, Inc. Chief Financial Officer Jason A. Leverone reported an automatic sale of 301 shares of Class A Common Stock. The shares were sold on March 23, 2026 at a weighted average price of $4.1565 per share.
According to the disclosure, the shares were automatically sold to cover tax withholding obligations tied to the vesting of restricted stock units under OnKure’s 2023 RSU Equity Incentive Plan, rather than as a discretionary trade. Following this tax-related sale, Leverone directly holds 16,000 shares of Class A Common Stock.
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision small-molecule drugs targeting mutated PI3Kα in cancer, led by its oral H1047R‑selective inhibitor OKI‑219. OKI‑219 is in a multi-arm Phase 1 PIKture‑01 trial in solid tumors, including PI3KαH1047R‑mutated breast cancer, with early data showing a favorable tolerability profile and no hyperglycemia, stomatitis or rash observed as of an October 28, 2024 cutoff.
The company highlights a sizable commercial opportunity in PI3Kα‑mutated HR+/HER2‑ and HER2+ breast cancer and is also advancing a pan‑mutant PI3Kα discovery program and work in vascular malformations. However, it has no approved products, has incurred significant net losses, has never generated product revenue, and management has concluded that substantial doubt exists about its ability to continue as a going concern without additional capital.
OnKure Therapeutics, Inc. reported fourth quarter and full-year 2025 results alongside updates on its PI3Kα‑focused oncology pipeline. Cash and cash equivalents were $59.1 million as of December 31, 2025, compared with $110.8 million a year earlier, reflecting continued investment in clinical development.
For Q4 2025, research and development expenses were $10.7 million and general and administrative expenses were $3.4 million, both below Q4 2024 levels. Net loss for the quarter was $13.5 million, or $0.99 per share, versus $17.4 million, or $1.37 per share, in Q4 2024.
Full-year 2025 net loss was $59.5 million, or $4.40 per share. Operationally, the company highlighted progress for lead candidate OKI‑219 in the PIKture‑01 phase 1 study, including completed enrollment in early trial parts and ongoing triplet combination arms, with multiple data readouts and a next‑generation PI3Kα pan‑mutant candidate announcement expected in 2026.
OnKure Therapeutics reports beneficial ownership disclosures by ADAR1-related holders. ADAR1 Capital Management, LLC is reported to beneficially own 1,014,158 shares of Class A common stock, representing 7.9% of the class, based on 12,861,672 shares outstanding as of November 5, 2025. The holdings include 793,602 shares held by ADAR1 Partners, LP, 119,064 shares held by Spearhead Insurance Solutions IDF, LLC and 101,492 shares held by separately managed accounts, all reported as of December 31, 2025.
ADAR1 Capital Management GP, LLC is shown with 793,602 shares (6.2%) and Daniel Schneeberger is reported to indirectly beneficially own 1,014,158 shares (7.9%) through his managerial roles. The filing is a joint Schedule 13G with a joint filing agreement and signatures dated 02/17/2026.
Citadel-affiliated investment entities and Kenneth Griffin report a passive minority stake in OnKure Therapeutics, Inc. They may be deemed to beneficially own 223,125 Class A common shares, representing 1.7% of the company’s outstanding stock based on 12,861,672 shares outstanding as of November 18, 2025.
Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC each may be deemed to beneficially own 48,957 shares, while Citadel Securities LLC, Citadel Securities Group LP and Citadel Securities GP LLC each may be deemed to beneficially own 174,168 shares. The reporting group certifies the holdings are not for the purpose of changing or influencing control of OnKure.
OnKure Therapeutics, Inc. received an updated ownership report from Highbridge Capital Management, LLC, filed as Amendment No. 1 to a Schedule 13G. Highbridge, a Delaware investment adviser, reports beneficial ownership of 542,361 shares of OnKure’s Class A common stock.
This stake represents 4.2% of the outstanding Class A common stock, based on 12,861,672 shares outstanding as of November 5, 2025 as disclosed in OnKure’s Form 10-Q for the quarter ended September 30, 2025. Highbridge has sole voting and dispositive power over these shares and certifies they are held in the ordinary course of business, not to change or influence control of the company.
OnKure Therapeutics Inc received an updated institutional ownership report from The Vanguard Group, which beneficially owns 626,593 shares of OnKure common stock, representing 4.87% of the class as of the reported date. Vanguard reports no sole voting or dispositive power, but shared voting power over 44,116 shares and shared dispositive power over all 626,593 shares.
The filing notes that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries or divisions are expected to report beneficial ownership separately while pursuing the same investment strategies. Vanguard states the securities are held in the ordinary course of business for its clients and not to change or influence control of OnKure.
OnKure Therapeutics, Inc. is registering 1,507,685 shares of its Class A common stock for resale by investors who bought these shares in an October 4, 2024 private PIPE financing. This is a secondary offering only, so all sale proceeds will go to the selling securityholders, while OnKure will cover registration and listing expenses.
The shares may be sold from time to time by the selling securityholders using various methods, including market and privately negotiated transactions, at market or negotiated prices. OnKure’s Class A common stock trades on Nasdaq under the symbol “OKUR,” and the last reported sale price on November 20, 2025 was $2.62.
As context, there were 12,861,672 shares of Class A common stock and 686,527 shares of non-voting Class B common stock outstanding as of September 30, 2025. Class B shares are convertible into Class A shares subject to a beneficial ownership cap that initially limits holders to 9.9% of outstanding Class A shares.